2017 News Releases

Keyword Search
 
2017 | 2016 | 2015
DateTitle 
February 06, 2017Opiant Pharmaceuticals, Inc. Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer
SANTA MONICA, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced the appointment of Phil Skolnick, Ph.D., D.Sc. (hon.) as Chief Scientific Officer, effective immediately. In his new position, Dr. Skolnick will lead Opiant’s research and development activities.     “I am delighted to welcome Dr. Skolnick to th... 
Printer Friendly Version
January 31, 2017Opiant Pharmaceuticals, Inc. Announces Establishment of Audit, Compensation and Nominating and Corporate Governance Committees
Company to pursue up-listing to a major stock exchange in 2017 SANTA MONICA, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that the Company’s Board of Directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. Copies of the Committee charters... 
Printer Friendly Version
January 26, 2017Opiant Pharmaceuticals, Inc. Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray
2mg Formulation Indicated for Patients At-Risk for Severe Opioid Withdrawal SANTA MONICA, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that the U.S. Food and Drug Administration has approved the 2mg formulation of NARCAN® Nasal Spray for opioid-dependent patients expected to be at risk for severe opioid w... 
Printer Friendly Version
January 11, 2017Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals
- Plans to Initiate Phase 2 Study in Bulimia Nervosa - - Company to Pursue Uplisting to a Major Stock Exchange - SANTA MONICA, Calif., Jan. 11, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced the company’s 2017 corporate and clinical goals. These corporate and clinical goals include Phase 2 clinical trial initiation, ongoin... 
Printer Friendly Version
January 09, 2017Opiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN® Nasal Spray and Heroin Vaccine Development
SANTA MONICA, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, was recently featured in several publications highlighting NARCAN® Nasal Spray and Opiant’s development of a treatment for heroin addiction. In MedCity News, an article titled “In 2016, the opioid epidemic hit home” notes Opiant’s development of NARCAN® Nasal S... 
Printer Friendly Version
Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet